Insider trading

Following insiders.

Send me real-time posts from this site at my email

Morgan Stanley Downgrades Jazz Pharmaceuticals As Stock Approaches Price Target

Morgan Stanley analyst wants to move to the sidelines on Jazz Pharmaceuticals PLC JAZZ as the stock has gained around 34 percent year-to-date and approached his price target of $183.

Morgan Stanley's David Risinger downgraded the stock from Overweight to Equal-Weight. Source

Upside starts to lose it's force, stochastics are getting closer to the overbought zone. the price will test the lower edge soon. 

$JAZZ, Jazz Pharmaceuticals plc - Ordinary Shares / D